Sentences with phrase «biopharmaceutical companies in»

In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests and technologies for various cancer therapies, helping to realize the promise of precision oncology.

She then took a position as an associate consultant at Kantar Health assisting biopharmaceutical companies in forecasting the market potential of new drugs.

We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally.

Retrophin later disclosed the investigation and sued Shkreli for $ 65 million, claiming he breached his duty of loyalty to the biopharmaceutical company in a long - running dispute over his use of company funds.

When a scientist posts a publication, users who are linked to the paper or cited in it receive notifications, a function biotechnologist Douglas Jolly, from Tocagen, a biopharmaceutical company in San Diego, California, uses «to track who is citing me and my collaborators.»

In 2002, deCODE Genetics, a biopharmaceutical company in Reykjavik, Iceland, reported evidence of a connection between neuregulin 1 and schizophrenia.

Kelly Scientific is seeking candidates for a document control project in a biopharmaceutical company in...

SUMMARY Self - Motivated, accomplished, enthusiastic and focused Professional Healthcare Representative with over 20 years of outstanding sales success with the largest Biopharmaceutical Company in the industry.

Not exact matches

• BridgeBio Pharma, a Palo Alto, Calif. - based clinical - stage biopharmaceutical company, raised $ 135 million in funding.

• FLX Bio Inc, a South San Francisco - based biopharmaceutical company focused on activating the immune system against cancer, raised $ 60 million in Series C funding.

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

Of 12 major, large - cap biopharmaceutical companies examined by Deloitte, the industry appears to be homing in on cancer therapies — and for a good economic reason.

• Zai Lab Limited, a Shanghai - based biopharmaceutical company, raised $ 30 million in Series C funding.

The firm also has active positions in medical equipment manufacturer Zimmer Biomet Holdings Inc., biopharmaceutical company Bristol - Myers Squibb Co., jeweler Tiffany & Co. and Blackhawk Network Holdings Inc..

Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical - stage biopharmaceutical company focused on the development of antibody - drug conjugates (ADCs) that was acquired by a consortium led by Fosun Pharmaceutical Group in 2015.

Biopharmaceutical company Parexel confirmed Tuesday morning it will be acquired by Pamplona Capital for $ 88.10 per share in cash, in a transaction valued at approximately $ 5 billion.

• Outpost Medicine, an Indianapolis and London - based biopharmaceutical company focused on treating urologic and gastrointestinal disorders, raised $ 20 million in funding.

• Arsanis, a Waltham, Mass. - based clinical stage biopharmaceutical company focused on monoclonal antibodies, raised $ 40 million in an offering of 4 million shares at $ 10 a piece, below its $ 15 to $ 17 range.

The best stock performer in the 500 - stock index, though, was biopharmaceutical company Nektar with a 78 percent gain over the past three months.

To this end, Calico has also forged a partnership with a Chicago - based biopharmaceutical company called AbbVie, in order to develop drugs that will tackle aging and age - related diseases such as neurodegeneration and cancer.

BOZEMAN, Mont., April 5, 2018 / PRNewswire / — SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announces the addition of some of the world's leading medical and scientific experts in the treatment of acute and chronic pain to its Scientific Advisory Board.

FORTUNE — One of America's most far - seeing companies, Vertex Pharmaceuticals, the biopharmaceutical startup so memorably chronicled in journalist Barry Werth's classic book, The Billion Dollar Molecule: The Quest for the Perfect Drug, is back.

To drive home that point, the combined company renamed itself Allergan in June — just six weeks ago — then bought Kythera Biopharmaceuticals (KYTH) for $ 2.1 billion.

«His expertise in successfully building commercial - ready operations at multiple biopharmaceutical companies will be instrumental as Nohla enters its next phase of growth.»

• Vicarius Pharma AG, a Switzerland - based which provides U.S. - based biopharmaceutical companies a new approach to commercializing assets in European markets, raised $ 21.8 million in funding.

Both Price and Gottlieb were questioned on their intimate involvement with biopharmaceutical and health care companies by lawmakers; Price specifically was the subject of sharp ethics questions about his financial investments in medical firms that would also benefit from legislation he was pushing while serving in the House of Representatives.

• Aptinyx Inc., an Evanston, Ill. - based clinical - stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, raised $ 70 million in Series B funding.

• Lundbeck agreed to acquire Prexton Therapeutics, a Netherlands - based biopharmaceutical company, for 100 million euros ($ 123 million) and will later pay up to 805 million euros ($ 989 million) in development and sales milestones.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

QS Investors LLC now owns 75,620 shares of the biopharmaceutical company's stock worth $ 2,358,000 after purchasing an additional 3,771 shares in the last quarter.

American International Group Inc. now owns 51,539 shares of the biopharmaceutical company's stock worth $ 1,607,000 after purchasing an additional 2,255 shares in the last quarter.

Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company's stock worth $ 145,000 after purchasing an additional 2,698 shares in the last quarter.

Crestline Management LP now owns 68,856 shares of the biopharmaceutical company's stock worth $ 2,147,000 after purchasing an additional 3,437 shares in the last quarter.

Swiss National Bank now owns 119,600 shares of the biopharmaceutical company's stock worth $ 3,729,000 after purchasing an additional 2,800 shares in the last quarter.

The Company's academic, biotechnology, and pharmaceutical customers use its consumable products and services in laboratory applications and in biopharmaceutical manufacturing.»

On Friday, August 4, 2017, a federal court jury in Brooklyn, New York, found Martin Shkreli, former CEO of biopharmaceutical company Retrophin, guilty on three of eight counts of securities fraud.

Shares of Human Genome Sciences doubled in Thursday morning trading on news that a major British biopharmaceutical company offered to buy it for $ 2.6 billion, which the Rockville company rejected as too low.Human Genome, which uses the human DNA...

Abeona Therapeutics Inc was founded back in 1974; this biopharmaceutical company develops methods of curing rare and life - threatening genetic diseases.

Durect, Corp., a biopharmaceutical company developing therapeutics based on its epigenetic regulator program and proprietary drug delivery platforms, posted an all - time low of 61 cents in November 2012 before embarking on an uptrend that topped out at $ 3.42 in June 2015.

Logo of global biopharmaceutical company Bristol - Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018.

Chimerix, a biopharmaceutical company that develops antivirals in areas of high unmet medical need, announced in a press release that a Phase 3 study for its SUPPRESS of brincidofovir in patients undergoing...

Governor Andrew Cuomo's office announced last week, that a large biopharmaceutical company will be investing millions of dollars with the aim of creating a manufacturing and development center at Pfizer's large campus in Pearl River.

«MedImmune's postdoctoral program, launched in 2011, is designed to cultivate and encourage the scientific leaders of tomorrow and help provide them a «launching pad» into careers within the biopharmaceutical industry and academia,» says a company statement provided to Science Careers.

In addition to his tenure at Lilly, he also consulted for various biopharmaceutical and health insurance companies on federal and state policy, sales, marketing, pricing, reimbursement, access and distribution.

As I reported in April, I had the opportunity to meet some industry postdocs at the Leaders of Tomorrow (LOT) Summit, held at the Gaithersburg, Maryland, headquarters of MedImmune, the biologics R&D arm of the international biopharmaceutical company AstraZeneca.

Part of the reason for that tight market is that industrial careers in plant biology are more limited in scope than those in, say, biopharmaceuticals, where the industry is filled with many companies and opportunities.

To top it off, this person had to have a Ph.D. in the life sciences and speak the language of the biopharmaceutical company.

In December 2006, Eli Lilly and Company announced it was to invest up to $ 400 million (US$ 532 million) in a program to establish a biopharmaceuticals development and manufacturing facility in KinsalIn December 2006, Eli Lilly and Company announced it was to invest up to $ 400 million (US$ 532 million) in a program to establish a biopharmaceuticals development and manufacturing facility in Kinsalin a program to establish a biopharmaceuticals development and manufacturing facility in Kinsalin Kinsale.

The survey asked each participant to list the companies that she or he regarded as the best, average, and worst employers in the biotechnology, biopharmaceutical, pharmaceutical, and related fields.

In April 2011, TransMolecular's tumour - targeter was snapped up by biopharmaceutical company Morphotek, a US - based subsidiary of Japanese drug giant Eisai.